Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FRE.DE

€45.51

Updated: 22/09/2026, 12:38:17

Market Cap
€25.63B
Sector
Healthcare
Industry
Medical - Care Facilities
Country
DE
Stock valuation chart
One-year closing share-price history for FRE.DE
Company Profile

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.

EUR
XETRA
CEO: Michael Sen
Employees: 178,486
https://www.fresenius.com
Asset Summaries
Latest generated summaries for FRE.DE

No summaries found.

Detailed business
The latest official filing is available; structured extraction is pending.
FRE.DE-geschaeftsbericht-fy2026.pdf14.1 MBapplication/pdfDE

The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.

Full company information
Latest profile, trading, valuation, and identifier data stored for FRE.DE.
Share price
€45.51
Market cap
€25.63B
Exchange
XETRA
Currency
EUR
CEO
Michael Sen
Employees
178,486
IPO date
09/11/1998
Beta
0.835
Last dividend
€0.00
Day range
€44.96 – €45.54
52-week range
€35.11 – €52.96
1-day performance
0.91%
1-year performance
29.62%
Current drawdown (1Y)
-14.07%
CIK
N/A
CUSIP
N/A
ISIN
DE000FRE5EN2
Created
07/09/2026, 05:15:41
Last update
22/09/2026, 12:38:17

Track Fresenius SE & Co. KGaA with an AI analyst

See which prediction-market events move FRE.DE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to FRE.DE from your Railway `news_articles` table.

No news found for this symbol.